Your browser doesn't support javascript.
loading
Observational management of papillary microcarcinoma appearing in the remnant thyroid after hemithyroidectomy.
Noda, Takuya; Miyauchi, Akira; Ito, Yasuhiro; Kudo, Takumi; Sano, Tsutomu; Sasaki, Takahiro; Ando, Takahito; Yamamoto, Masatoshi; Fujishima, Makoto; Masuoka, Hiroo; Higashiyama, Takuya; Kihara, Minoru; Onoda, Naoyoshi; Miya, Akihiro.
Afiliação
  • Noda T; Department of Head and Neck Surgery, Kuma Hospital, Kobe 650-0011, Japan.
  • Miyauchi A; Department of Surgery, Kuma Hospital, Kobe 650-0011, Japan.
  • Ito Y; Department of Surgery, Kuma Hospital, Kobe 650-0011, Japan.
  • Kudo T; Department of Internal Medicine, Kuma Hospital, Kobe 650-0011, Japan.
  • Sano T; Department of Head and Neck Surgery, Kuma Hospital, Kobe 650-0011, Japan.
  • Sasaki T; Department of Head and Neck Surgery, Kuma Hospital, Kobe 650-0011, Japan.
  • Ando T; Department of Surgery, Kuma Hospital, Kobe 650-0011, Japan.
  • Yamamoto M; Department of Surgery, Kuma Hospital, Kobe 650-0011, Japan.
  • Fujishima M; Department of Surgery, Kuma Hospital, Kobe 650-0011, Japan.
  • Masuoka H; Department of Surgery, Kuma Hospital, Kobe 650-0011, Japan.
  • Higashiyama T; Department of Surgery, Kuma Hospital, Kobe 650-0011, Japan.
  • Kihara M; Department of Surgery, Kuma Hospital, Kobe 650-0011, Japan.
  • Onoda N; Department of Surgery, Kuma Hospital, Kobe 650-0011, Japan.
  • Miya A; Department of Surgery, Kuma Hospital, Kobe 650-0011, Japan.
Endocr J ; 69(6): 635-641, 2022 Jun 28.
Article em En | MEDLINE | ID: mdl-34955475
ABSTRACT
Active surveillance for papillary thyroid microcarcinomas (PTMCs) initiated in Japan is becoming adopted worldwide as a management option. However, it remains unclear how to manage newly appearing PTMCs in the remnant thyroid after hemithyroidectomy. We investigated the outcomes of similar observational management (OM) for PTMCs appearing in the remnant thyroid after hemithyroidectomy for papillary thyroid carcinoma (PTC) and benign thyroid nodules. Eighty-three patients were newly diagnosed with PTMC in the remnant thyroid between January 1998 and March 2017. Of these, 42 patients underwent OM with >3 times ultrasound examinations. Their initial diagnoses were PTC (initially malignant group) in 37 patients and benign nodule (initially benign group) in 5 patients. We calculated the tumor volume doubling rate (TV-DR) during OM for each PTMC. The TV-DR (/year) was <-0.1, -0.1-0.1, 0.1-0.5, and >0.5 in 12, 19, 5, and 6 patients, respectively. The TV-DRs in both groups did not statistically differ, but six patients (16%) in the initially malignant group showed moderate growth (TV-DR >0.5/year). They underwent conversion surgery and none of them had further recurrence. The remaining 36 patients retained OM without disease progression. The TV-DR in the initially malignant group was not significantly associated with patients' backgrounds or their initial clinicopathological features. None of the patients in this study showed distant metastases/recurrences or died of thyroid carcinoma. Although a portion of PTMCs appearing after hemithyroidectomy for thyroid malignancy are moderately progressive, OM may be acceptable as a management option for PTMCs appearing in the remnant thyroid after hemithyroidectomy.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Glândula Tireoide / Carcinoma Papilar Limite: Humans Idioma: En Revista: Endocr J Assunto da revista: ENDOCRINOLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Japão

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Glândula Tireoide / Carcinoma Papilar Limite: Humans Idioma: En Revista: Endocr J Assunto da revista: ENDOCRINOLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Japão